EP0533834A4 - - Google Patents

Info

Publication number
EP0533834A4
EP0533834A4 EP91912402A EP91912402A EP0533834A4 EP 0533834 A4 EP0533834 A4 EP 0533834A4 EP 91912402 A EP91912402 A EP 91912402A EP 91912402 A EP91912402 A EP 91912402A EP 0533834 A4 EP0533834 A4 EP 0533834A4
Authority
EP
European Patent Office
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91912402A
Other versions
EP0533834A1 (en
Inventor
James C Paulson
Mary S Perez
Federico C A Gaeta
Robert Murray Ratcliffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytel Corp
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of EP0533834A1 publication Critical patent/EP0533834A1/en
Publication of EP0533834A4 publication Critical patent/EP0533834A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP91912402A 1990-06-15 1991-06-14 Intercellular adhesion mediators Withdrawn EP0533834A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US538853 1983-10-04
US53885390A 1990-06-15 1990-06-15
US61931990A 1990-11-28 1990-11-28
US619319 1990-11-28
US63239090A 1990-12-21 1990-12-21
WOPCT/US91/03592 1991-05-22
PCT/US1991/003592 WO1991019501A1 (en) 1990-06-15 1991-05-22 Intercellular adhesion mediators
PCT/US1991/004284 WO1991019502A1 (en) 1990-06-15 1991-06-14 Intercellular adhesion mediators
US632390 2000-08-04

Publications (2)

Publication Number Publication Date
EP0533834A1 EP0533834A1 (en) 1993-03-31
EP0533834A4 true EP0533834A4 (en) 1995-04-19

Family

ID=27415280

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91912402A Withdrawn EP0533834A1 (en) 1990-06-15 1991-06-14 Intercellular adhesion mediators

Country Status (12)

Country Link
EP (1) EP0533834A1 (en)
AU (2) AU8007791A (en)
BR (1) BR9106556A (en)
CA (1) CA2084888A1 (en)
FI (1) FI925668A (en)
HU (1) HU216312B (en)
IE (1) IE912048A1 (en)
IL (1) IL98493A (en)
NO (1) NO924830L (en)
NZ (1) NZ238556A (en)
SG (1) SG52563A1 (en)
WO (2) WO1991019501A1 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576305A (en) * 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US5753631A (en) * 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5648344A (en) * 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
US5211936A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a cite of inflammation utilizing elam-1 ligands site
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
DE69233654D1 (en) * 1991-04-19 2006-10-19 Univ Leland Stanford Junior COMPOSITIONS AND METHODS OF CONNECTING ENDOTHELIAL CELLS
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
EP0588852A1 (en) * 1991-06-10 1994-03-30 Glycomed Incorporated Immunosuppressive and tolerogenic oligosaccharide derivatives
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
GB9114657D0 (en) * 1991-07-06 1991-08-21 Antisoma Ltd Diagnostic compounds
WO1993005803A1 (en) * 1991-09-25 1993-04-01 Genetics Institute, Inc. Anti-inflammatory selectin inhibitors
WO1993008802A1 (en) * 1991-10-31 1993-05-13 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing tricyclic compound
GB9208339D0 (en) * 1992-04-15 1992-06-03 Unilever Plc Treatment composition
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
EP0652897A4 (en) * 1992-05-28 1995-09-20 Centocor Inc Peptide inhibitors of selectin binding.
WO1993024526A1 (en) * 1992-05-28 1993-12-09 Centocor, Inc. Peptide inhibitors of selectin binding
CA2100412A1 (en) * 1992-07-15 1994-01-16 Yutaka Yamada Glycolipid derivatives
AU677216B2 (en) * 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US5753617A (en) * 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
ATE210452T1 (en) * 1992-10-02 2001-12-15 Alberta Res Council ANTI-INFLAMMATORY TOLEROGENE AND IMMUNOINHIBITORY PROPERTIES OF CARBOHYDRATE BINDING PEPTIDES
US6406894B1 (en) 1992-12-11 2002-06-18 Glycorex Ab Process for preparing polyvalent and physiologically degradable carbohydrate-containing polymers by enzymatic glycosylation reactions and the use thereof for preparing carbohydrate building blocks
EP0601417A3 (en) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologically compatible and degradable polymer-based carbohydrate receptor blockers, a method for their preparation and their use
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
AU6353294A (en) * 1993-03-01 1994-09-26 Glycan Pharmaceuticals, Inc. Analogs for specific oligosaccharide-protein interactions and uses therefor
CA2157489A1 (en) * 1993-03-04 1994-09-15 Masaaki Numata Lewis-associated compound, process for producing the same, and anti-inflammatory
US5811404A (en) * 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5854218A (en) * 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
DE69430253T2 (en) 1993-05-17 2002-11-14 Avant Immunotherapeutics Inc COMPLEMENT RELATED PROTEINS AND CARBOHYDRATES CONTAINING COMPOSITIONS AND METHODS FOR THE PRODUCTION AND USE OF THESE COMPOSITIONS
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US5559103A (en) * 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5783693A (en) * 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995013819A1 (en) * 1993-11-19 1995-05-26 The Regents Of The University Of California Sulfated ligands for l-selectin and methods of preventing sulfate addition
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
DE4408248A1 (en) * 1994-03-11 1995-09-14 Hoechst Ag Physiologically acceptable and physiologically degradable carbohydrate mimetics, process for their preparation and their use
DE4431280A1 (en) 1994-09-02 1996-03-07 Hoechst Ag Process for the isolation and purification of nucleotide-activated sugars from biological sources
JPH10508580A (en) * 1994-09-20 1998-08-25 ファルマシア・アンド・アップジョン・カンパニー Oligosaccharide structures of ligands for E and P selectins
DE4436164A1 (en) * 1994-10-10 1996-04-11 Hoechst Ag New conjugates of tetra:carbohydrate and amide-linked peptide or dye etc.
US5599915A (en) * 1995-03-21 1997-02-04 The Scripps Research Institute Sialyl Lewis X mimetics
US5614615A (en) * 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
EP1428832A3 (en) * 1995-08-03 2004-09-22 The Board of Regents for the University of Oklahoma Peptide and O-glycan inhibitors of selectin mediated inflammation
DE69632176T2 (en) * 1995-08-17 2005-04-14 The Biomembrane Institute, Seattle Anti-inflammatory compounds
US5876715A (en) * 1995-08-17 1999-03-02 The Biomembrane Institute Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof
SK39498A3 (en) * 1995-09-29 1999-01-11 Glycim Oy Synthetic multivalent slex containing polylactosamines and methods for use
AU7445796A (en) * 1995-10-18 1997-05-07 Cytel Corporation Sialyl lex analogues as inhibitors of cellular adhesion
AU1122897A (en) * 1995-11-13 1997-06-05 Glycomed Incorporated Novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties
EP0902681B1 (en) * 1996-03-01 2002-05-22 The Regents of the University of California Inhibition of selectin binding
WO1997037682A1 (en) * 1996-04-10 1997-10-16 Cytel Corporation Nucleic acids encoding gdp-fucose pyrophosphorylase
US5830871A (en) * 1996-10-28 1998-11-03 The Scripps Research Institute Inhibitors of E-, P- and L-selectin binding
EP0834572A3 (en) * 1996-10-02 1999-08-25 F. Hoffmann-La Roche Ag Alpha, gamma-diaminobutyric acid (DAB) containing oligopeptide derivatives
JP2001515912A (en) 1997-09-05 2001-09-25 グリシム オサケ ユキチュア Synthetic divalent sLex-containing polylactosamines and methods of use
ES2568899T3 (en) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of an immunofunctional molecule
GB0015923D0 (en) * 2000-06-30 2000-08-23 Astrazeneca Ab Methods
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7127357B1 (en) 2000-12-08 2006-10-24 The Salk Institute For Biological Studies Crystal structure of WW domains and methods of use thereof
PL367102A1 (en) 2001-05-02 2005-02-21 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
WO2002089819A1 (en) * 2001-05-07 2002-11-14 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Glycoconjugates and uses thereof
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
ES2317010T3 (en) 2003-05-30 2009-04-16 Purdue Research Foundation METHOD OF DIAGNOSIS OF ARTEROSCLEROSIS.
JPWO2005011633A1 (en) * 2003-08-01 2006-09-14 独立行政法人産業技術総合研究所 Inflammatory disease therapeutic agent or diagnostic agent containing targeting liposome
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
PT1934236E (en) 2005-09-02 2012-12-26 Glycomimetics Inc Heterobifunctional pan-selectin inhibitors
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation Ex vivo flow cytometry method and device
AU2008213702B2 (en) 2007-02-07 2014-04-24 Purdue Research Foundation Positron emission tomography imaging method
EP2164525A2 (en) 2007-05-25 2010-03-24 Purdue Research Foundation Method of imaging localized infections
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
NZ593816A (en) 2009-01-22 2012-11-30 Momenta Pharmaceuticals Inc Galactose-alpha-1, 3-galactose-containing n-glycans in glycoprotein products derived from cho cells
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
EP3296310A1 (en) 2011-12-22 2018-03-21 GlycoMimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
HUE038423T2 (en) 2012-12-07 2018-10-29 Glycomimetics Inc Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
WO2016089872A1 (en) 2014-12-03 2016-06-09 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US11045485B2 (en) 2016-01-22 2021-06-29 Glycomimetics, Inc. Glycomimetic inhibitors of PA-IL and PA-IIL lectins
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
WO2018031445A1 (en) 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
WO2018068010A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
EP3596096A1 (en) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
JP7304863B2 (en) 2017-12-29 2023-07-07 グリコミメティクス， インコーポレイテッド Heterobifunctional inhibitors of E-selectin and galectin-3
CA3091454A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0283337A (en) * 1988-09-18 1990-03-23 Nichirei Corp Diagnostic agent for cancer and recovery of tumor marker using the same agent
WO1990013300A1 (en) * 1989-04-28 1990-11-15 Biogen, Inc. ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)
WO1992007572A1 (en) * 1990-10-25 1992-05-14 Regents Of The University Of Michigan Agents and methods for binding to elam-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0283337A (en) * 1988-09-18 1990-03-23 Nichirei Corp Diagnostic agent for cancer and recovery of tumor marker using the same agent
WO1990013300A1 (en) * 1989-04-28 1990-11-15 Biogen, Inc. ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs)
WO1992007572A1 (en) * 1990-10-25 1992-05-14 Regents Of The University Of Michigan Agents and methods for binding to elam-1

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
B.K.BRANDLEY ET AL.: "Carbohydrate Ligands of the LEC Cell Adhesion Molecules", CELL, vol. 63, 30 November 1990 (1990-11-30), pages 861 - 863, XP023908144, DOI: doi:10.1016/0092-8674(90)90487-Y *
C.K.CHING ET AL.: "PURIFICATION AND CHARACTERIZATION OF A PEANUT-AGGLUTININ-BINDING PANCREATIC-CANCER-RELATED SERUM MUCUS GLYCOPROTEIN", J.CANCER, vol. 45, no. 6, 15 June 1990 (1990-06-15), pages 1022 - 1027, XP000605191, DOI: doi:10.1002/ijc.2910450607 *
C.UNDERHILL ET AL.: "THE ROLE OF HYALURONIC ACID IN INTERCELLULAR ADHESION OF CULTERED MOUSE CELLS", EXP.CELL RES., vol. 117, no. 1, 1978, pages 155 - 164, XP024790889, DOI: doi:10.1016/0014-4827(78)90438-X *
D.TYRRELL ET AL.: "Structural requirements for the carbohydrate ligand of E-selectin", PROC.NATL.ACAD.SCI. U.S.A., vol. 88, no. 22, November 1991 (1991-11-01), pages 10372 - 10376, XP000562667, DOI: doi:10.1073/pnas.88.22.10372 *
DATABASE WPI Derwent World Patents Index; AN 90-135674 *
E.L.BERG ET AL.: "A Carbohydrate Domain Common to Both Sialyl Lea and Sialyl Lex Is Recognized by the Endothelial Cell Leukocyte Adhesion Moloecule ELAM-1", J.BIOL.CHEM., vol. 266, no. 23, 15 August 1991 (1991-08-15), pages 14869 - 14872, XP000652121 *
J.B.LOWE ET AL.: "ELAM-1-Dependent Cell Adhesion to Vascular Endothelium Determined by a Transfected Human Fucosyltransferase cDNA", CELL, vol. 63, no. 3, 2 November 1990 (1990-11-02), pages 475 - 484, XP023907995, DOI: doi:10.1016/0092-8674(90)90444-J *
L.J.PICKER ET AL.: "The Neutrophil Selectin LECAM-1 Presents Carbohydrate Ligands to the Vascular Selectins ELAM-1 and GMP-140", CELL, vol. 66, no. 5, 6 September 1991 (1991-09-06), pages 921 - 933, XP023908303, DOI: doi:10.1016/0092-8674(91)90438-5 *
M.L.PHILLIPS ET AL.: "ELAM-1 Mediates Cell Adhesion by Recognition of a Carbohydrate Ligand, Sialyl-Lex", SCIENCE, vol. 250, no. 4984, 23 November 1990 (1990-11-23), pages 1130 - 1132, XP000601651, DOI: doi:10.1126/science.1701274 *
M.TIEMEYER ET AL.: "Carbohydrate ligands for endothelial-leukocyte adhesion molecule 1", PROC.NATL.ACAD.SCI. U.S.A., vol. 88, February 1991 (1991-02-01), pages 1138 - 1142, XP000562666, DOI: doi:10.1073/pnas.88.4.1138 *
P.H.JOHNSON ET AL.: "Sialyl compounds as acceptor substrates for the human alpha-3- and alpha-3/4-L-fucosyltransferases", BIOCHEM.SOC.TRANS., vol. 13, no. 6, 1985, pages 1119 - 1120 *
S.D.ROSEN ET AL.: "Lymphocyte attachment to high endothelial venules during recirculation: A possible role for carbohydrates as recognition determinants", MOL.CELL.BIOCHEM., vol. 72, no. 1-2, November 1986 (1986-11-01), pages 153 - 164 *
See also references of WO9119502A1 *

Also Published As

Publication number Publication date
CA2084888A1 (en) 1991-12-16
WO1991019501A1 (en) 1991-12-26
SG52563A1 (en) 1998-09-28
FI925668A0 (en) 1992-12-14
NO924830L (en) 1993-02-08
EP0533834A1 (en) 1993-03-31
AU660931B2 (en) 1995-07-13
HUT69652A (en) 1995-09-28
AU8007791A (en) 1992-01-07
IL98493A (en) 1998-12-06
NO924830D0 (en) 1992-12-14
HU216312B (en) 1999-06-28
IE912048A1 (en) 1991-12-18
NZ238556A (en) 1994-01-26
WO1991019502A1 (en) 1991-12-26
AU8102991A (en) 1992-01-07
BR9106556A (en) 1991-12-26
HU9204091D0 (en) 1993-11-29
FI925668A (en) 1992-12-14

Similar Documents

Publication Publication Date Title
EP0533834A4 (en)
DE4190587T (en)
DE9001666U1 (en)
DE9003356U1 (en)
DE4191068T (en)
DE9001432U1 (en)
DE4092623T1 (en)
DE9003155U1 (en)
DE9002292U1 (en)
DE9002100U1 (en)
DE9001429U1 (en)
DE9000277U1 (en)
DE9001065U1 (en)
DE4190245T (en)
DE9003195U1 (en)
DE9002541U1 (en)
DE4190534T (en)
DE9001968U1 (en)
DE9002533U1 (en)
DE9001047U1 (en)
DE9001003U1 (en)
DE9001503U1 (en)
DE9003170U1 (en)
DE9001088U1 (en)
DE9001254U1 (en)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

D17D Deferred search report published (deleted)
A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000102